Browse through our press and news section by category:

03.06.2015, SCHOTT AG, Istanbul / Turkey

CPhI Istanbul: SCHOTT and Vinder to support Turkish Pharma Industry with Excellence in Primary Packaging

adaptiQ® Ready-to-use Solutions and syriQ™ Glass Syringes on Display at Booth D57
SCHOTT will present its Syringe Portfolio at CPhI Istanbul.
Photo ID: 163529
SCHOTT will present its Syringe Portfolio at CPhI Istanbul. Photo ID: 163529
Together with their Turkish partner company Vinder SCHOTT presents new packaging solutions at CPhI Istanbul (June 3-5) that will bring the Turkish pharmaceutical industry a major step forward. Boot D57 at the ICC Istanbul Congress Center will feature SCHOTT’s innovation in pharma glass vials and syringes which are designed to offer maximum shelf-life stability and reduced total cost of ownership to pharma companies. Amongst them are SCHOTT adaptiQ® ready-to-use vials which provide a new generation of possibilities for Turkish pharma companies in their effort to lower invest and reduce running costs.

adaptiQ® Ready-to-use vials
Ready-to-use vials such as SCHOTT adaptiQ® represent a new production concept offering two main advantages: First, they are already sterilized when delivered to the pharma company or contract filler who can then load the vials directly onto the filling line. Second, the vials are fixed in a nest so there is no glass to glass contact during the entire filling process, including lyophilization. This helps to reduce the reject rate and also preserves the cosmetic quality of the vials. SCHOTT developed the concept in close collaboration with filling-line manufacturers to ensure utmost processability. As a result the pharma companies can fill multiple drug / container configurations on the same filling lines with less downtime in between. SCHOTT has started to gradually introduce adaptiQ® in all common ISO formats, from 2R to 30R. Samples are available for evaluation. At CPhI Istanbul the solution will also be presented during a speech by SCHOTT expert Florence Buscke (June 3, 13:15 h: “SCHOTT ready-to-use containers – Added customer value through forward integration”).

Complete Syringe Portfolio
To offer pharmaceutical companies a broad range of solutions, SCHOTT has developed a complete portfolio of both glass and polymer syringes. In the field of glass syringes, the offerings range from 0.5 to 3 Milliliter (ml) products, suitable for a broad variety of applications like heparin, vaccines, biotech, and special applications. All glass syringes are available with luer lock, luer cone or with staked needle. SCHOTT has been manufacturing glass and polymer syringes in Europe for more than 14 years. The production facility in St. Gallen, Switzerland, has developed into a center of excellence and is supported by an R&D team based at the site.

Partner of the Turkish pharma industry
“The Turkish pharmaceutical market is gaining momentum. With the country’s goal to become one of the largest drug exporters by 2025, more and more new companies are entering the Turkish pharmaceutical market. To develop successful drug products it is more important than ever for Turkish drug manufacturers and experienced packaging suppliers to join forces,” said Rüdiger Wagner, Sales Director in Eastern Europe, Turkey and Israel for SCHOTT Pharmaceutical Systems. “Vinder and SCHOTT form a strong partnership which helps the Turkish pharma industry to achieve their growth targets,” added Laki Vingas, Managing Director of Vinder Dis Ticaret Ve Pazarlama A.S.

About SCHOTT
SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products and intelligent solutions. SCHOTT is an innovative enabler for many industries, including the home appliance, pharmaceutical, electronics, optics, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 35 countries. With its workforce of approximately 15,400 employees, sales of 1.87 billion euros were generated in fiscal year 2013/2014. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.
SCHOTT’s adaptiQ® ready-to-use vials offer two main advantages: they are already sterilized and fixed in a nest, so there is no glass to glass contact. 
Photo ID: 215956
SCHOTT’s adaptiQ® ready-to-use vials offer two main advantages: they are already sterilized and fixed in a nest, so there is no glass to glass contact. Photo ID: 215956
Press contact
SCHOTT AG
Christina Rettig
Public Relations Manager
Hattenbergstraße 10
55122 Mainz
Phone: +49 6131/66-4094
Further information
SCHOTT AG
Salvatore Ruggiero
Vice President Marketing and Communication
Hattenbergstraße 10
55122 Mainz
Phone: +49 6131/66-4140
SCHOTT uses Cookies on this Website to enhance the user experience and provide the best possible Service. By continuing to browse the Website, you consent to our use of Cookies.